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530 H. Su et al.injured musculocutaneous nerve of rats, they survived robustly, extended axons along the nerve, and formed functional
connections with the target muscle (biceps brachii), thereby protecting the muscle from atrophy. Our study provides evidence
for the first time that human iPSC-derived motoneurons are truly functional not only in vitro but also in vivo, and they have
potential for stem cell-based therapies for motoneuron diseases.
© 2013 Elsevier B.V. All rights reserved.Introduction
Induced pluripotent stem cells (iPSCs) are promising for the
treatment of neurological diseases because of their fascinat-
ing features: they are pluripotent, self-derived, and easily
obtainable (Takahashi and Yamanaka, 2006; Yu et al., 2007).
Many studies have shown that human iPSCs can successfully
differentiate into functional neuronal subtypes such as
dopaminergic neurons (Hargus et al., 2010; Rhee et al.,
2011; Soldner et al., 2009) and motoneurons (Dimos et al.,
2008; Hu et al., 2010; Karumbayaram et al., 2009), opening
an avenue for clinical application of iPSC technology in the
near future. Motoneuron diseases are characterized by
degeneration of motoneurons, clinically manifesting with
progressive paralysis and muscle wasting. There are current-
ly no efficacious treatments for these diseases. Recently cell
replacement strategies have been applied to treat neurolog-
ical disorders with motoneuron degeneration (Corti et al.,
2008, 2010; Deshpande et al., 2006; Gao et al., 2005).
Grafted mouse embryonic stem cell (ESC)-derived motoneu-
rons are reported to survive, extend axons into ventral roots,
and promote functional recovery in rodent models of
motoneuron degeneration, initiating hopes of successful
cell replacement for degenerating motoneurons in the spinal
cord (Corti et al., 2009; Deshpande et al., 2006; Harper et
al., 2004). However, ethical concerns and immune rejection
greatly hamper the clinical application of ESCs as sources for
cell therapy (Testa et al., 2007; Lui et al., 2009).
Human iPSCs may be an appealing cell source for treating
motoneuron diseases. They are reprogrammed to an embryonic
state from human adult somatic cells (such as skin fibroblasts)
by introducing pluripotency factors (Takahashi et al., 2007; Yu
et al., 2007), which provides the opportunity for cell
replacement therapy without ethical conflicts and requiring
immunosuppressive therapy to overcome immune rejection.
Recent studies have reported that human iPSCs can success-
fully differentiate into functional motoneurons using a
chemically-defined in vitro system (Dimos et al., 2008; Ebert
et al., 2009; Hu and Zhang, 2010; Karumbayaram et al., 2009),
suggesting their therapeutic potential. However, a number of
fundamental questions remain unanswered: whether iPSC-
derived neurons can survive and integrate into the host and,
more importantly, whether they can functionally innervate
their targets after transplantation in vivo. In addition, it
remains to be elucidated whether there are any potential risks
associated with transplantation of iPSC-derivatives in vivo such
as carcinogenesis resulting either from overexpression of an
oncogene or through insertional mutagenesis into the host
genome.
Using the rat model of brachial plexus injury, we
investigated the survival, axonal extension and functional
innervation of human iPSC-derived motoneurons after direct
transplantation into the rat musculocutaneous nervefollowing brachial plexus injury. The results of the study
provide evidence for the potential of iPSC-based therapies
for the treatment of motoneuron diseases.
Materials and methods
Human iPSC culture and neuronal differentiation
The human iPSC line (hi-UMC) was derived from mesenchymal
cells of the human umbilical cord matrix using exogenous
factors (Cai et al, 2010). Briefly, 40,000 cells per well from
human umbilical cords at early passage were transduced in
6-well culture dishes using pMX-based retroviruses (Adgene).
Transduced cells were maintained in high glucose DMEM
(Hyclone) + 20% hESC-defined FBS (DFBS, Hyclone), nonessen-
tial amino acids, penicillin/streptomycin, l-glutamine,
β-mercaptoethanol, and bFGF (Invitrogen). From day 7, plates
were either maintained in DFBS-containingmedium or switched
to KSR-based medium (DMEM/F12 + 20% knock-out serum
replacement, nonessential amino acids, penicillin/streptomy-
cin, l-glutamine, β-mercaptoethanol, and bFGF). Picked
hi-UMC colonies were cultured on feeder layers using KSR
medium, or on Matrigel (BD Biosciences) using mTeSR1 medium
(Stemcell). Hi-UMC showed human embryonic stem cell
(hESC)-like characteristics includingmorphology, positive stain-
ing for alkaline phosphatase, normal karyotype, expression of
hESC-like markers including Nanog, Rex1, Oct4, TRA-1–60,
TRA-1–80, SSEA-3, and SSEA-4, and the ability to form
embryonic bodies and teratomas containing derivatives of the
3 germ layers.
The hi-UMC and human ESC line H9 were maintained and
differentiated according to previously described methods (Hu
and Zhang, 2009; Li et al., 2005). Briefly, iPSCs and ESCs were
cultured and passagedweekly in ESCmedium (DMEM/F12 + 20%
knockout serum replacement, nonessential amino acids, peni-
cillin/streptomycin, L-glutamine, beta-mercaptoethanol, and
bFGF) on a feeder layer of irradiated embryonic mouse
fibroblasts. After detachment from feeder cells and culture in
suspension in ESC medium lacking FGF2 for 4 days, aggregates
of human iPSCs and ESCs referred to as embryoid bodies (EBs)
were treated with neural medium consisting of DMEM/F12, N2
supplement, nonessential amino acids and heparin for an
additional 2 days. EBs were then seeded on laminin-coated
dishes to generate neuroepithelial cells in neural medium
for 4 days. Human iPSC-derived neuroepithelial cells at day
10 were first treated with retinoic acid (RA, 0.1 μM) for
caudalization in neural medium. The posteriorized
neuroectodermal cells formed tube-like neural rosettes. Four
days later (day 14), neural rosettes were gently blown off and
suspended in the same neural medium. RA (0.1 μM) and sonic
hedgehog (SHH, 200 ng/ml) were used for inducing the ventral
spinal progenitor fate for 1 week, leading to an efficient
531Transplanted human induced pluripotent stem cells-derived motoneuronsinduction of motoneuron progenitors that were identified by
Olig2 expression (day 21). For differentiation of post-mitotic
motoneurons, the Olig2-expressing progenitor clusters were
grown on laminin substrate. Neurotrophic factors, brain-
derived neurotrophic factor (BDNF, 20 ng/ml), glial-derived
neurotrophic factor (GDNF, 20 ng/ml), ciliary neurotrophic
factors (CNTF, 20 ng/ml), insulin-like growth factor-1 (IGF1,
10 ng/ml), and cAMP (1 μM) were added to support the survival
and process outgrowth of motoneurons.
Fluorescence-activated cell sorting
To quantify the neural differentiation potential of human iPSCs,
cell clusters at day 14 and day 21 were fixed directly for
fluorescence-activated cell sorting (FACS) analysis. After
digestion with Accutase (Innovative Cell Technologies Inc., San
Diego), cell clusters were dissociated to single cells, andwashed
with FACS buffer. After being fixed and permeabilized with
ice-cold 0.1% paraformaldehyde for 10 min and 90% methanol
for 30 min, cells from cell clusters at day 14 were incubated in
primary antibody (Pax6, mouse IgG; 1:5000) and cells from cell
clusters at day 21 were incubated in primary antibody (Olig2,
goat IgG; 1:1000). Cells were then washed and incubated with
the corresponding secondary antibody, FITC-conjugated
anti-mouse or anti-goat IgG, for 2 h followed by washing
steps. Cells were analyzed using a Becton Dickinson FACSCalibur
instrument and CellQuest Pro software (BD Biosciences, San
Diego).
Immunocytochemisty and quantification
Immunocytochemical staining on coverslip cultures and
quantification were performed as previously described (Lee
et al., 2007; Su et al., 2009) and primary antibodies were
listed in Table 1. Species-specific secondary antibodies
conjugated to the fluorescent labels Alexa 568 or 488 (1:400;
Molecular Probes) were used to visualize primary antibodies.
Cells were mounted in anti-fade medium containing 4′
6-diamidino-2-phenylindole (DAPI, Sigma) to counterstain
nuclei. To quantify cells expressing Tuj1, Hoxb4, Hb9, Islet1,
Lhx3 and ChAT, 8-9 representative fields per well were
randomly selected and digitized images were obtained with
a 20× objective using a cooled CCD digital camera. Five wellsTable 1 Primary antibody list.
Antibodies Isotype Dilution Sour
Pax6 Mouse IgG 1:2,000 Dev
SOX1 Goat IgG 1:1,000 R&D
Nestin Rabbit IgG 1:1,000 Sigm
OLIG2 Goat IgG 1:500 Sant
HOXB4 Rat IgG 1:50 Dev
Islet1 Mouse IgG 1:400 Dev
hNuclei Mouse IgG 1:200 Che
Lhx3 Mouse IgG 1:500 Dev
HB9 Mouse IgG 1:50 Dev
ChAT Goat IgG 1:200 Che
hNF70 Mouse IgG 1:200 Che
Tuj1 Rabbit IgG 1:5,000 Cov
α-BT NA 1:500 Moleper experiment were imaged. Cells were counted on images
imported and processed using a semi-automatic stereology
system with Stereo Investigator (MicroBrightField, Williston,
VT). Results are the average ± SEM of data from five
experiments unless stated otherwise.
Animal surgery and cell transplantation
Adult female Sprague-Dawley rats (220–250 g) were used.
After anesthesia with intraperitoneal injection of ketamine
(80 mg/kg) and xylazine (8 mg/kg), the right C5, C6 and C7
root avulsion was performed to detach themusculocutaneous
nerve from the spinal cord. Immediately after root avulsion,
animals received either cell transplantation (n = 12) or
vehicle injection (n = 12). For cell preparation, neural
rosettes after 14 days of differentiation were gently blown
off and suspended in the neural medium. RA (0.1 μM) and
sonic hedgehog (SHH, 200 ng/ml) were used for inducing the
ventral spinal progenitor fate for 1 week, leading to an
efficient induction of motoneuron progenitors that were
identified by Olig2 expression. Suspended cell clusters after
treatment with RA and SHH at day 21 were dissociated with
Accutase into single cells and re-suspended in NB medium
with 20 μg/ml BDNF, 20 μg/ml GDNF, 20 μg/ml CNTF and
10 μg/ml IGF at a concentration of 1.0 × 105 cells/μl, and
placed on ice for the duration of the grafting session. Cell
viability was assessed with trypan blue at the end of
transplantation and typically over 90% of the cells excluded
the dye. One microliter cell suspension or vehicle (NB
medium plus the cocktail of neurotrophic factors described
above) was slowly injected into the right musculocutaneous
nerve. After cell injection, the proximal end of the
musculocutaneous nerve was ligated to confine the injec-
tant. Animals were allowed to survive for 16 weeks (12 rats
per group). Cyclosporin A (10 mg/kg, Sigma) was injected
intramuscularly daily to suppress immune rejection during
the whole survival period.
Electrophysiological analysis
Whole-cell patch-clamp recordings
Whole-cell patch-clamp recording techniques were used to
study the intrinsic properties of umbilical cord-iPSC-derivedce Cat. no.
elopmental Studies Hybridoma Bank Pax6
Systems AF3366
a N5413
a Cruz Biotechnology SC-19969
elopmental Studies Hybridoma Bank 112 anti-Hoxb4
elopmental Studies Hybridoma Bank 40.3A4
micon MAB1281
elopmental Studies Hybridoma Bank 67.4E12





532 H. Su et al.motoneurons in culture. Patch pipettes (resistance 3–5 MΩ)
were filled with the following (in mM): 140 potassium
methanesulfonate, 10 HEPES, 5 NaCl, 1 CaCl2, 0.2 EGTA, 3
ATP-Na2, 0.4 GTP-Na2, pH 7.3 (adjusted with KOH). The
external solution contained (in mM): 120 NaCl, 1.2 KH2PO4,
1.9 KCl, 26 NaHCO3, 2.2 CaCl2, 1.4 MgSO4, 10 D-glucose, 7.5
HEPES (pH with NaOH to 7.3). The bath solution was
equilibrated with 95% O2 and 5% CO2 before use. Resting
potentials were maintained at about −65 mV. Whole-cell
patch-clamp recordings were amplified and filtered using an
Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA).
Signals were sampled at 10 kHz using a Digidata 1440A
analog-to-digital converter and acquired and stored on a
computer hard drive using pClamp10 software. All voltage and
current-clamp recordings were performed as described
previously (Miles et al., 2004). Data were analyzed using
pClamp10 (Clampfit).
Electromyographic measurement (EMG)
At the end of the study, animals were killed, and the
musculocutaneous nerve and biceps brachii muscle were
quickly removed and transferred into a recording chamber
that was continuously perfused with room-temperature
oxygenated mouse Tyrode's solution (in mM: 125 NaCl, 24
NaHCO3, 5.4 KCl, 1 MgCl2, 1.8 CaCl2, and 5% dextrose) at aFigure 1 Hi-UMC exhibited high efficiency in neural differentiat
neural tube-like rosettes at day 14 (B), and expressed the neural epit
colonies (D), formed neural tube-like rosettes at day 14 (E), and exp
both hi-UMC and H9 exhibited a high efficiency in generating Pax6-
Scale bar: 100 μm for A, B, D, and E; 25 μm for C and F.flow rate of 4–5 ml/min. EMG recordings were obtained
using a suction electrode on the surface of the muscle while
a second suction electrode was used to stimulate the nerve.
EMG signals were amplified with a differential amplifier
(EX4-400, Dagan) and captured using Axoscope 9.2 software
(Molecular Devices).Tissue analysis
The biceps brachii muscle was weighed after EMG recording.
Themusculocutaneous nerve and biceps brachii were then fixed
in 3.7% formaldehyde and cryo-sectioned at 30 μm. Longitudi-
nal nerve sections were incubated with the primary antibodies
including human Nuclei, human-specific neurofilament 70, Hb9
and ChAT to indentify the survival, maturation and axonal
extension of transplanted human iPSC-derived motoneurons.
The total number of human Nuclei-expressing cells was counted
in every fourth section. To detect phenotypes of transplanted
cells, we stained three tissue sections per rat for each neuronal
marker and then counted the number of the cells with the
positive staining of the neuronal marker in 10 random fields per
section at 40× magnification using the confocal microscope. All
quantification was performed in an unbiased stereological
manner. Biceps brachii muscle sections were incubated withion. A–C: Human ESCs grew as individual colonies (A), formed
helial marker (NE) Pax6 (C). D–F: Human iPSCs grew as individual
ressed Pax6 (F). G and H: At day 14, FACS analyses revealed that
expressing NE cells (64.8 ± 7.5% and 85.3 ± 6.1% respectively).
533Transplanted human induced pluripotent stem cells-derived motoneurons1 μg/ml of rhodamine-conjugated α-bungarotoxin (Molecular
Probes) for 1 h at room temperature and double-labeled with
human-specific neurofilament 70 to visualize transplanted
human cell-derived acetylcholine receptors (ACHRs).
Statistical analysis
Data are expressed as mean ± SEM. Student's two-tailed
t-test was used for comparison of two experimental groups.
Changes were identified as significant if pwas less than 0.05.
Results
Hi-UMC showed high efficiency in neural differentiation
and generated functional motoneurons in vitro
A schematic illustration was used to show our experimental
design (Fig. S1). Using a well-established protocol (Hu and
Zhang, 2009; Li et al., 2005), we firstly investigated the neural
differentiation capacity of hi-UMC which was derived from
mesenchymal cells of the umbilical cord (Cai et al., 2010).
Human iPSCs were cultured in ESCmedium on a feeder layer of
irradiated embryonic mouse fibroblasts. They grew as round
colonies and were morphologically indistinguishable from
human ESCs, such as exhibiting a large nucleus and multiple,
prominent nucleoli (Figs. 1A and D). By 10–14 days differen-
tiation, both human ESCs and iPSCs successfully generated
columnar neuroepithelial cells and formed typical neural
tube-like rosettes (Figs. 1B and E). Immunostaining showed
that the columnar cells in the rosettes expressed early neural
epithelial (NE) marker Pax6 (Figs. 1C and F). FACS analyses
demonstrated that both hi-UMC and H9 exhibited high
efficiency in generating Pax6-expressing NE cells (64.8 ±
7.5% and 85.3 ± 6.1% respectively) (Figs. 1G and H).
We then investigated motoneuron differentiation of
hi-UMC. By 10 days differentiation, typical neural tube-like
rosettes were formed (Fig. 2A). Cells in the rosettes became
positive for Sox1 and a small proportion were positive for
Nestin (Fig. 2B). We therefore treated the NE cells with RA at
day 10 for motoneuron specification. Four days later, many
cells were found to express HOXB4, suggesting that the
primitive NE cells were induced into progenitors with spinal
cord identity by RA treatment (Figs. 2D and K; 57.5 ± 4.7% of
total Tuj1-positive cells). From day 15, after lifting off rosettes
and treatment with RA and SHH for 1 week, an efficient
induction of motoneuron progenitors identified by Olig2
expression was obtained (Fig. 2C). FACS analysis demonstrated
that around 75.5 ± 8.1% cells were Olig2-positive (Fig. 2J). We
replated these Olig2-expressing progenitor clusters onto
laminin-coated dishes and added a cocktail of neurotrophic
factors and cAMP to support their survival and outgrowth
(Fig. 2E). These Olig2-expressing cells then differentiated into
motoneurons in the 5th week and expressed Hb9 (Figs. 2F and
K; 31.2 ± 5.6% of total Tuj1-positive cells) and Islet1 (Figs. 2G
and K; 28.6 ± 3.6% of total Tuj1-positive cells). When further
cultured in the presence of neurotrophic factors and cAMP,
some cells became Lhx3-positive (Figs. 2H and K; 19.4 ± 2.7%
of total Tuj1-positive cells). Expression of Lhx3 in motoneuron
progeny suggests that a subset of hiPSC-derived motoneurons
expressed medial motor column markers. Cells that expressed
ChAT, a key enzyme catalyzing acetylcholine synthesis forsignal conduction, appeared in the 5th week (3 weeks after
the neuroectodermal cells were plated for motoneurons
differentiation). The number of ChAT-positive cells increased
steadily and reached a high level at 5 weeks after plating of
the neuroectodermal cells (Figs. 2I and K; 64.5 ± 5.2% of total
Tuj1-positive cells).
Standard whole-cell patch clamp recordings were then
performed to investigatewhether themolecular characteristics
of iPSC-derived motoneurons were accompanied by the
acquisition of functional properties typical of mature motoneu-
rons (n = 25) (Fig. 3A). Voltage-clamp recordings demonstrated
that most cells generated large, rapidly-inactivating inward
currents in response to depolarizing voltage steps that were
sensitive to TTX (10 μM) (Fig. 3B), and persistent outward
currents activated by depolarizing steps from a holding
potential of -100 mV that were sensitive to TEA (30 μM)
(Fig. 3C). Using current-clamp recordings, roughly half of
tested neurons generated repetitive trains of action potentials,
suggesting that they were functional (Fig. 3D). All these data
demonstrated that hi-UMC can successfully develop into
phenotypically and physiologically mature motoneurons in
vitro. After recordings were made, the neurons were fixed
and double immunostaining with biocytin and ChAT demon-
strated that many of the cells which we recorded were
motoneurons (data not shown).Transplanted hi-UMC-derived motoneurons survived
and extended axons in the musculocutaneous nerve
These functional human iPSC-derived motoneurons are attrac-
tive for cell-based therapies for motoneuron diseases. Howev-
er, whether they survive after transplantation in vivo, and
more importantly, whether they can form functional connec-
tions with target muscles are critical for evaluating their
therapeutic potential. Using the brachial plexus injury model,
we transplanted hi-UMC-derived motoneuron progenitors
directly into the musculocutaneous nerve to investigate their
survival, maturation, axonal extension and functional inner-
vation of the target muscles (Fig. 4A). Compared to the central
nervous system, the peripheral nervous system is more
favorable for cell survival, closer to the target muscles and
less affected by endogenous neuronal circuits, thus facilitating
assessment of the ability of grafted cells to survive and
reinnervate their targets (Thomas et al., 2000; Yohn et al.,
2008). By 16 weeks after transplantation, robust graft survival
was observed in the musculocutaneous nerve as evidenced by
immunohistochemistry for human Nuclei (Fig. 4B). Approxi-
mately 1.8 × 104 human Nuclei-positive cells were found in the
nerve, representing that 18% of initial grafted cells survived at
16 weeks after transplantation. We co-labeled these human
Nuclei-positive cells with a human specific neuronal marker,
human specific neurofilament 70, and found that around
71.5 ± 6.2% of them were human specific neurofilament
70-positive (Figs. 4B, b and C). Furthermore, immunostaining
with ChAT and Hb9 showed that grafted hiPSC-derived cells
could give rise to ChAT-positive and Hb9-positive motoneurons
in the nerve (Figs. 5A, B, a and c).
We then examined axonal extension of graft-derived
motoneuron-like cells in the musculocutaneous nerve. Double
immunostaining with human specific neurofilament 70 and
ChAT demonstrated that human specific neurofilament
Figure 2 Neural patterning and motoneuron derivation from hi-UMC. A: Phase contrast photographs of neural rosettes from
hi-UMC. B: Cells in neural rosettes expressing Sox1 and Nestin. C: Immunostaining for Olig2 shows efficient generation of motoneuron
progenitors. D: RA treatment sufficiently patterns NE cells to Hoxb4-positive progenitors with upper spinal cord identity. E: Phase
contrast photographs of iPSC-derived motoneurons. F, G, H and I: HB9, Islet, Lhx3 and ChAT staining showed mature iPSC-derived
motoneurons. J: FACS analysis demonstrated that treatment with RA and SHH for 1 week led to an efficient induction of
Olig2-positive motoneuron progenitors (75.5 ± 8.1%). K: The percentages of motoneurons which expressed specific neuronal marks
were counted and represented as the mean ± SEM. Scale bar: 120 μm for A; 35 μm for B, C and D; 60 μm for E-I.
534 H. Su et al.70-positive axons were present throughout the transected
nerve and clearly shown to be co-labeled with ChAT,
suggesting they were extending from the cell graft towards
the nerve terminal (Fig. 5b).Transplanted hi-UMC-derived motoneurons formed
functional connections with the target muscle
To determine whether the terminals of iPSC-derived moto-
neurons formed synaptic connections with the target muscle,anti-human-specific neurofilament 70 antibody was used to
visualize human iPSC-derived motoneuron axons and
rhodamine-conjugated α-bungarotoxin (BT) was used to label
postsynaptic ACHRs at the motor endplates. Human-specific
neurofilament-positive axons were in close apposition to the
motor endplates at 16 weeks after transplantation (Fig. 6A),
whereas no neuromuscular junctions were co-labeled with
human-specific neurofilament antibody in vehicle control
(Fig. 6B) and normal control rats (Fig. 6C). We then proceeded
to stimulate the peripheral nerve in isolated nerve-muscle
preparations to induce EMG responses. Successful EMG
Figure 3 Human iPSC-derived motoneurons expressed voltage-activated Na+ and K+ currents and developed appropriate firing
properties. A: A phase contrast image showing that a whole-cell patch-clamp recording electrode attached on an iPSC-derived
motoneuron-like cell under an IR/DIC microscopy. B: Voltage-clamp recordings demonstrated large, rapidly-inactivating inward
currents in response to depolarizing voltage steps that were sensitive to TTX (10 μM). C: Voltage-clamp recordings showed persistent
outward currents activated by depolarizing steps from a holding potential of -100 mV that were sensitive to TEA (30 μM). D: Current
injections (300 ms duration current injections with increasing 5 pA every round) and single current injection (300 ms duration, 30 pA)
showing these motoneurons generated repetitive trains of action potentials. Scale bar: 10 μm.
535Transplanted human induced pluripotent stem cells-derived motoneuronsresponses were induced in all the animals with cell transplants
(Fig. 6F1), while no EMG response was found in vehicle control
animals at 12 weeks after injury (data not shown). To confirm
that the muscle contractions resulted from neurotransmission
by the transplanted iPSC-derived motoneurons, the compet-
itive nicotinic antagonist D-tubocurarine was added to the
recording solution. EMG activity was blocked by D-tubocura-
rine (Fig. 6F2) and this blockade was reversed after a 5-h
washout period (Fig. 6F3). These data indicated functional
innervation of biceps brachii by implanted iPSC-derived
motoneurons. In cell implanted animals, significantly more
neuromuscular junctions were found compared to vehicle
control animals (Fig. 6D; 8.1 ± 2.4 vs 1.3 ± 1.2 per mm2;
P b 0.05) and the muscle wet weight of biceps brachii muscle
from the cell implanted animals was nearly triple of that of
vehicle control animals (Fig. 6E; 68.4 ± 12% of normal side vs
23.5 ± 6 of normal side; P b 0.001), suggesting thattransplanted cells efficiently protected against the muscle
atrophy resulting from brachial plexus injury.Discussion
Stem cells-based replacement strategies show a promising
future for the treatment of motoneuron diseases due to their
ability to replace lost, damaged or dysfunctional neurons.
However, it still needs further studies to decide on which
stem cell type is the optimal cell source for transplantation
therapy. ESCs have been considered to be an ideal cell
source of motoneurons. Both murine and human ESCs are
able to differentiate into functional motoneurons when
exposed to SHH and RA (Li et al., 2005; Wichterle et al.,
2002). However, immune rejection and ethical controversy
greatly hurdle the clinical application of ESCs.
Figure 4 Transplanted hi-UMC-derived motoneurons survived in the nerve. A: Schematic figure showing the experimental paradigm
and design. B: Transplanted hi-UMC-derived cells were located at the injection site in the nerve as identified by anti-human Nuclei and
anti-human-specific neurofilament (hNF) antibody. (b): A confocal image under higher magnification showing the morphology of survived
neurons which co-labeled with anti-human Nuclei and anti-hNF. C: The percentage of hNF- positive neurons from transplanted
hi-UMC-derived cells (human Nuclei-positive) was counted and represented as the mean ± SEM. Scale bar: 80 μm for B; 20 μm for b.
536 H. Su et al.iPSCs seem to be an optimal cell source for transplantation
therapy. They have the advantage of eliminating ethical and
immune rejection concerns. The generation of iPSCs from a
patient's own somatic cells would potentially allow for a
plentiful source of cell therapeutics for autotransplantation. A
number of studies have reported that human iPSCs can
successfully differentiate into motoneurons (Dimos et al.,
2008; Ebert et al., 2009; Hu and Zhang, 2010; Karumbayaram
et al., 2009). However, all these studies did not investigate
the capacity of human iPSC-derived motoneurons for func-
tional innervation after transplantation in vivo.
In the present study, we demonstrated that human iPSCs
derived from mesenchymal cells of the umbilical cord
possess high efficiency in neural differentiation and can
efficiently differentiate into phenotypically and physiologi-
cally mature motoneurons in vitro. Using the model of the
musculocutaneous nerve and its target muscle, our study
investigated the survival and the capacity for functional
innervation of human iPSC-derived motoneurons after
transplantation in vivo. Our results showed that grafted
human iPSC-derived motoneurons not only survive well in
vivo but also are capable of forming functional connections
with target muscles. More importantly, they significantly
attenuated denervated muscle atrophy after transplantation
into the peripheral nerve close to the target muscle, which
may preserve endogenous motoneuron terminals and offer a
possibility of later formation of functional connections
between regenerating axons and denervated muscles. In
our surgical paradigm, the proximal end of the
musculocutaneous nerve was ligated to confine the injec-
tant; thus transplanted cells were disconnected to the
central nervous system. Using this paradigm, we answeredthe questions whether transplanted hiPSC-derived motoneu-
rons could survive and innervate into the target muscle in
vivo and demonstrated that hiPSC-derived motoneurons are
truly functional not only in vitro but also in vivo, setting the
basis for using hiPSC-derivatives to treat motoneuron
diseases.
No host-derived endogenous nerve connection with
the target muscle existed due to the ligation on the proximal
end of the musculocutaneous nerve. Graft-derived innervation
was revealed by staining with rhodamine-conjugated
α-bungarotoxin and human-specific neurofilament 70. Nearly
half of biceps brachii muscle fibers were innervated following
transplantation of hiPSCs-derived motoneurons. The extent of
reinnervation depended on the number of survived motoneu-
rons, the number of graft-derived myelinated axons and
functional motor units in the target muscle. Our study
demonstrated that transplantation of 1.0 × 105 hiPSC-derived
motoneurons results into significant re-innervation and func-
tional recovery. However, it remains unknown whether
transplantation of more neurons will lead to more innervation
and better functional recovery. Future work is needed to
explore the correlation between the timing of cell transplan-
tation and the efficiency of axonal regeneration and neuromus-
cular junction formation and the correlation between the
number of transplanted cells and the extent of reinnervation as
well.
In summary, our study provides evidence for the first time
on the in vivo survival and functional innervation of human
iPSC-derived motoneurons, a key requirement in the
development of iPSC-based cell therapy for motoneuron
diseases. It should be noted, however, that future studies
are essential regarding the capacity of human iPSC-derived
Figure 5 Transplanted hi-UMC-derived motoneurons survived, matured and extended axons along the nerve. A: Transplanted
hi-UMC-derived motoneurons were found to extend hNF-positive axons along the nerve towards the target muscle. (a1–a3) are
micrographs under higher magnification of the left outlined area in A showing that transplanted cells at the injection site expressed
ChAT, an enzyme catalyzing acetylcholine synthesis. (b1–b3) are micrographs under higher magnification of the right outlined area in
A showing hNF-positive axons co-labeled with ChAT. Scale bar: 350 μm for A; 50 μm for a1–a3; 60 μm for b1–b3. B: Hi-UMC-derived
Hb9-positive neurons in the nerve. Transplanted cells were located at the injection site in the nerve as identified by anti-hNF
antibody. (c1–c3) are micrographs under higher magnification of the outlined area in B by double-staining of anti-hNF and Hb9
antibodies. Scale bar: 75 μm for B; 25 μm for c1–c3.
537Transplanted human induced pluripotent stem cells-derived motoneuronsmotoneurons for long-distance axonal growth and the ability
to innervate appropriate peripheral targets. HiPSC-derived
motoneurons will be transplanted into the ventral horn of
the spinal cord of animals with motoneuron degeneration
such as amyotrophic lateral sclerosis (ALS) and spinal
muscular atrophy (SMA). We will investigate whether they
can survive and integrate into the local circuit in the ventral
horn, and whether they can find appropriate ways to grow
axons to innervate target muscles and improve functional
recovery. Results of these studies will help us fully address
the therapeutic potential of hiPSCs in cell replacement
strategies for the treatment with motoneuron degeneration
diseases.Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.02.007.
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Figure 6 Transplanted hi-UMC-derived motoneurons formed functional connections with the target muscle and reduced muscle
atrophy. A: Axon terminals labeled with a hNF antibody and α-bungarotoxin (α-BT)-labeled neuromuscular junctions (NMJs) showing
nerve terminals of human iPSC-derived motoneurons attached to NMJs. B and C: No NMJs were co-labeled with hNF in vehicle control
(B) and normal rats (C). D: The number of NMJs in cell implanted animals (n = 12) was significantly higher than in vehicle control
animals (n = 12) (8.1 ± 2.4 vs 1.3 ± 1.2 per mm2; P b 0.05). E: The wet weight of biceps brachii from the cell implanted animals was
nearly triple of that in vehicle control animals (n = 12 in each group, P b 0.001). F: Successful EMG responses were induced in animals
with cell transplants (F1); EMG responses were mediated through the NMJ, since application of D-tubocurarine effectively attenuated
EMG activity (F2), which recovered after a 5-h washout period (F3). Scale bar: 120 μm for A, B and C.
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